Article citationsMore>>

Oh, W.K., Galsky, M.D., Stadler, W.M., Srinivas, S., Chu, F., et al. (2011) Multicenter Phase II Trial of The Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients with Castration-Resistant Prostate Cancer. Urology, 78, 626-630.
https://doi.org/10.1016/j.urology.2011.04.041

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top